Company Profile
Swedish Orphan Biovitrum AB (publ), a biopharma company provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. Its operations are structured into three segments: Haematology, Immunology, and Specialty Care.
It offers Alprolix for haemophilia B. Its portfolio also includes ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A, Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria, Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia, Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A, Gamifant for treating hemophagocytic lymphohistiocytosis, Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis, Orfadin for hereditary tyrosinemia type 1 and alkaptonuria, Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children, VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis, and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma, as well as other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer.
The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Incorporated in 1939, the company is headquartered in Stockholm, Sweden.